Overview Treatment of Upper Extremity Deep-Vein Thrombosis Status: Completed Trial end date: 2011-12-01 Target enrollment: Participant gender: Summary The purpose of this study is to document the long-term outcome or prognosis of patients diagnosed with upper extremity deep-vein thrombosis who are treated with Fragmin (dalteparin sodium injection) for three months. Phase: Phase 4 Details Lead Sponsor: University of OklahomaCollaborator: PfizerTreatments: DalteparinHeparin, Low-Molecular-WeightTinzaparinWarfarin